Active material: Finasteride
When ATH: G04CB01
CCF: Drug for the treatment of benign prostatic hyperplasia. Ингибитор 5a-редуктазы
When CSF: 28.01.01.01
Manufacturer: DR. REDDY`S LABORATORIES LTD. (India)
Pills, Film-coated white, round, lenticular, со знаком “FIN” на одной стороне и гладкие – с другой; на изломе – белая или почти белая масса.
| 1 tab. | |
| finasteride | 5 mg |
Excipients: docusate sodium, sodium carboxymethyl starch (Type A), pregelatinized corn starch, lactose, magnesium stearate, microcrystalline cellulose (Ultra-102).
The composition of the coating film: gipromelloza (15 cps), propylene glycol, talc, Titanium dioxide.
10 PC. – стрипы (3) – пачки картонные.
Финастерид – синтетическое 4-азастероидное соединение, конкурентный и специфический ингибитор стероидной 5-альфа редуктазы – внутриклеточного фермента, which converts testosterone to 5-active androgen DHT (DGT). Tissue growth and development of prostate benign hyperplasia due to the conversion of testosterone to dihydrotestosterone in the prostate cells. Under the influence of the drug is a significant decrease in the concentration digidrosterona in blood plasma, and in prostate tissue. Finasteride does not bind to androgen receptors.
As a result of the drug decreases the size of the prostate, decreases symptoms, associated with BPH.
The drug had no effect on plasma lipid levels and cortisol levels, Estradiol, prolactin, TSH, tiroksina.
Absorption and distribution: After oral administration of finasteride is rapidly absorbed from the gastrointestinal tract. Bioavailability is about 80% and independent of food intake
Maximum plasma concentration is achieved in 1-2 hours after oral administration. Plasma protein binding is about 90%.
Metabolism and excretion: Finasteride is metabolized by the liver and is excreted as metabolites in the urine and feces.
Pharmacokinetics in special cases: the half-life of the drug in patients over 60 s is 6 hours, in patients over 70 years can be extended to 8 hours.
Finasta appoint 5 mg 1 once a day, regardless of the meal.
Duration of therapy to assess its effectiveness must not be less than 6 months. Approximately 50% patients with disappearance of clinical symptoms occurred during the treatment 12 months.
Allergic reactions, gynecomastia, impotence, reduced libido and decrease in ejaculate volume. The incidence of side effects than 3-4% and decreases during treatment. In some cases, there was increase in the level of luteinizing hormone and follicle-stimulating hormone and testosterone by approximately 10%, however, these parameters remained within normal limits.
These are not represented.
Before treatment is necessary to eliminate the disease Finasta, which may simulate benign prostatic hyperplasia, such as infectious prostatitis, prostate cancer, urethral stricture, hypotonic bladder, and a number of changes in the urinary system, occur in some diseases of the nervous system.
With care prescribe a drug to patients with impaired hepatic function.
Since the application of Finasta decrease prostate-specific antigen (on 41% and 48% according to 6 and 12 months of therapy), periodically during therapy is necessary to conduct a survey of patients to avoid their prostate cancer.
Women of childbearing age and pregnant women should avoid contact with the crushed pills Finasta, tk. the ability of the drug to inhibit the conversion of testosterone to DHT can cause developmental disorders of sex organs in a male fetus
Currently, cases of drug overdose were reported Finasta.
No clinically significant drug interactions.
The drug should be stored in a dry, dark place at temperatures up to 25 ° C.
Keep out of reach of children!
Shelf life: 2 year.
Do not use beyond the expiration date, on the package.
This site uses cookies and services to collect technical data from visitors to ensure performance and improve the quality of service.. By continuing to use our site, you automatically agree to the use of these technologies.
Read More